Pacific Biosciences of California PACB
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 47th percentile, 5-year average -12.3x
Near the bottom of its 5-year range · 6th percentile, 5-year average 14.8x
Around its usual level · 46th percentile, 5-year average 9.4x
#3581 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -10.00 | – | 14.76 | 6% (cheaper than usual) | – |
| PE | -4.67 | -4.12 | -12.33 | 47% (cheaper than usual) | – |
| PS | 3.80 | 3.60 | 9.36 | 46% (cheaper than usual) | #3581 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PACB.
Sign in to join the discussion.